NCT05707767 is a NA clinical trial of Resection surgery in Chordoma of Spine, sponsored by Xuanwu Hospital, Beijing.

Who is sponsoring NCT05707767?

NCT05707767 is sponsored by Xuanwu Hospital, Beijing.

What drugs are being tested in NCT05707767?

Interventions in NCT05707767: Resection surgery.

What condition does NCT05707767 study?

NCT05707767 studies Chordoma of Spine, Surgery.

Is NCT05707767 still recruiting?

NCT05707767 is currently status unknown. Last updated 19 July 2023.

Last reviewed 2023-07-19 · How we verify

NCT05707767

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective Study of Surgical Treatment Strategies for Chordoma

Status unknown NA Last updated 19 July 2023

What this trial tests

NA trial testing Resection surgery in Chordoma of Spine in 100 participants. Status unknown.

Timeline

1 February 2023

Primary endpoint
30 September 2024

30 September 2024

Quick facts

Lead sponsor	Xuanwu Hospital, Beijing
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 February 2023
Primary completion	30 September 2024
Estimated completion	30 September 2024
Sites	1 location across China

Drugs / interventions tested

Resection surgery

Conditions studied

Chordoma of Spine — all drugs for Chordoma of Spine →
Surgery — all drugs for Surgery →

Sponsor

Xuanwu Hospital, Beijing

Who can join

Adults 18 to 70, any sex, with Chordoma of Spine or Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chordoma is a rare but locally invasive cancer that arises from the embryonic notochord. Total resection is challenging in mobile spine because of the complex anatomy and bone invasion.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Chordoma: Genetics and Contemporary Management.
Desai R, Pelargos PE, Dunn IF. · · 2024 · cited 15× · PMID 38892063 · DOI 10.3390/ijms25115877

Verify or expand the search:

Other trials of Resection surgery

Trials testing the same drug.

NCT06395337 — Multimodal Imaging in Rectal Cancer & Pancreatic Cancer · Phase 1, PHASE2 · unknown

Other Xuanwu Hospital, Beijing trials

Trials by the same sponsor.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05707767 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
Last refreshed: 19 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05707767.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing